Plant formulation ATRICOV 452 in improving the level of COVID-19 specific inflammatory markers in patients

Damle, Latha; Damle, Hrishikesh; BR, Bharath

doi:10.1016/j.conctc.2022.100961

Cited by 2 publications

(4 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As of October 1, 2022, 119 preprints (78.3%) had been published in a scientific, peer-reviewed journal (Figure 2 and eTable 3 in Supplement 1). Two preprints were published in a single journal publication . The median time to publication was 186 days (range, 17-407 days).…”

Section: Resultsmentioning

confidence: 98%

Comparison of Preprint Postings of Randomized Clinical Trials on COVID-19 and Corresponding Published Journal Articles

et al. 2023

View full text Add to dashboard Cite

ImportanceRandomized clinical trials (RCTs) on COVID-19 are increasingly being posted as preprints before publication in a scientific, peer-reviewed journal.ObjectiveTo assess time to journal publication for COVID-19 RCT preprints and to compare differences between pairs of preprints and corresponding journal articles.Evidence ReviewThis systematic review used a meta-epidemiologic approach to conduct a literature search using the World Health Organization COVID-19 database and Embase to identify preprints published between January 1 and December 31, 2021. This review included RCTs with human participants and research questions regarding the treatment or prevention of COVID-19. For each preprint, a literature search was done to locate the corresponding journal article. Two independent reviewers read the full text, extracted data, and assessed risk of bias using the Cochrane Risk of Bias 2 tool. Time to publication was analyzed using a Cox proportional hazards regression model. Differences between preprint and journal article pairs in terms of outcomes, analyses, results, or conclusions were described. Statistical analysis was performed on October 17, 2022.FindingsThis study included 152 preprints. As of October 1, 2022, 119 of 152 preprints (78.3%) had been published in journals. The median time to publication was 186 days (range, 17-407 days). In a multivariable model, larger sample size and low risk of bias were associated with journal publication. With a sample size of less than 200 as the reference, sample sizes of 201 to 1000 and greater than 1000 had hazard ratios (HRs) of 1.23 (95% CI, 0.80-1.91) and 2.19 (95% CI, 1.36-3.53) for publication, respectively. With high risk of bias as the reference, medium-risk articles with some concerns for bias had an HR of 1.77 (95% CI, 1.02-3.09); those with a low risk of bias had an HR of 3.01 (95% CI, 1.71-5.30). Of the 119 published preprints, there were differences in terms of outcomes, analyses, results, or conclusions in 65 studies (54.6%). The main conclusion in the preprint contradicted the conclusion in the journal article for 2 studies (1.7%).Conclusions and RelevanceThese findings suggest that there is a substantial time lag from preprint posting to journal publication. Preprints with smaller sample sizes and high risk of bias were less likely to be published. Finally, although differences in terms of outcomes, analyses, results, or conclusions were observed for preprint and journal article pairs in most studies, the main conclusion remained consistent for the majority of studies.

show abstract

Section: Resultsmentioning

confidence: 98%

Comparison of Preprint Postings of Randomized Clinical Trials on COVID-19 and Corresponding Published Journal Articles

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Of the 163 articles identified, 12 studies were reckoned to meet the eligibility criteria and these articles were included for analysis (depicted in Figure 2). Out of 12 studies, 11 studies are conducted in COVID-19 patients [14][15][16][17][18][19][20][21][22][23][24] and 1 study is conducted in post-COVID-19 patients. 25 There are 22 varieties of plants involved as add-on therapy for COVID-19 patients.…”

Section: Resultsmentioning

confidence: 99%

“…It is interesting to find out that the aerial part of Andrographis paniculata plants (CIM-MEG19 tablet) has shown the best efficacy as an add-on therapy for COVID-19 patients. 14,19 This drug showed a statistically significant (p < 0.05) reduction in CRP (53.58%) and D-dimer (22.04%) levels as well as the ESR (erythrocyte sedimentation rate). However, an increase in IL-6 (21.88%) was observed, although in general, the patients in the Intervention Group showed no AEs or SAEs.…”

Section: Efficacymentioning

confidence: 94%

“…14 A. paniculata was also studied in a combination with other plants (ATRICOV 452 capsule) and resulted in a decrease of IL-6, CRP, and D-dimer levels. 19 Moreover, the bulb of garlic (Allium sativum) was studied as an add-on therapy in reducing CRP in mild-severity hospitalized patients with COVID-19. Although the result was not clinically significant compared to that of the placebo group, the add-on therapy using A. sativum could reduce 62.55% CRP level compared to the baseline.…”

Section: Efficacymentioning

confidence: 99%

See 1 more Smart Citation

Efficacy and Safety of Add-On Plant-Based Drugs for COVID-19 Patients: A Review of the Randomized Control Trials

Diantini¹,

Febriyanti²,

Levita³

2023

IDR

View full text Add to dashboard Cite

COVID-19 caused by the infection of SARS-CoV-2 is still a global concern. WHO reported that from 13 March to 9 April 2023, there were 3 million new cases and approximately 23,000 deaths, mostly occurring in the South-East Asia and Eastern Mediterranean regions, which is predicted due to the new Omicron variant, Arcturus XBB.1.16. Many studies have reported the potency of medicinal plants in enhancing the function of the immune system to combat virus infection. The literature review aimed to describe the efficacy and safety of add-on plant-based drugs for COVID-19 patients. The articles were explored on the PubMed and Cochrane Library databases, and published during 2020-2023. Twenty-two varieties of plants were used as add-on therapy for COVID-19 patients. These plants were

show abstract

Plant formulation ATRICOV 452 in improving the level of COVID-19 specific inflammatory markers in patients

Cited by 2 publications

References 23 publications

Comparison of Preprint Postings of Randomized Clinical Trials on COVID-19 and Corresponding Published Journal Articles

Comparison of Preprint Postings of Randomized Clinical Trials on COVID-19 and Corresponding Published Journal Articles

Efficacy and Safety of Add-On Plant-Based Drugs for COVID-19 Patients: A Review of the Randomized Control Trials

Contact Info

Product

Resources

About